MedTrace Logo

Apremilast and Adalimumab in Psoriatic Arthritis Patients

NCT07398651 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-02-10

No results posted yet for this study

Summary

The aim of this work is to compare the efficacy of Apremilast combined with Methotrexate versus Adalimumab combined with Methotrexate

Conditions

Interventions

DRUG

Adalimumab

PsA patients who will receive Adalimumab with methotrexate therapy for 3 months

DRUG

Apremilast

PsA patients who will receive Apremilast with methotrexate therapy for 3 months

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-12-30
Primary Completion
2026-12-30
Completion
2026-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07398651 on ClinicalTrials.gov